Skip to main content
. 2013 Oct 9;2:519. doi: 10.1186/2193-1801-2-519

Table 4.

Clinical data and laboratory tests in patients of the bleeding group categorized according to changes in serum sodium concentratio

Characteristics Non-decreased (n = 58) Decreased (n = 41) p value
Age 53.66 ± 10.14 58.54 ± 12.20 0.039
Sex 0.167
 Male (%) 49 (84.5) 30 (73.2)
 Female (%) 9 (15.5) 11(26.8)
Etiology of cirrhosis 0.507
 Alcoholics (%) 35 (60.3) 22 (53.7)
 Non-alcoholics (%) 23 (39.7) 19 (46.3)
Infusion of albumin 0.282
 Yes (%) 20 (34.5) 10 (24.4)
 No (%) 38 (65.5) 31 (75.6)
Cumulative dose of Terlipressin (mg) 14.21 ± 3.42 14.80 ± 3.39 0.391
Amount of hydration (L) 4.34 ± 1.77 4.64 ± 2.13 0.447
Amount of sodium infused (mEq) 341.25 ± 259.89 313.77 ± 321.40 0.652
Total bilirubin (0 ~ 1.2 mg/dL) 3.72 ± 5.37 2.44 ± 2.63 0.122
Albumin (3.4 ~ 4.8 g/dL) 2.60 ± 0.49 2.75 ± 0.55 0.162
Creatinine (0.6 ~ 1.2 mg/dL) 1.17 ± 0.51 1.03 ± 0.47 0.163
Hemoglobin (13 ~ 17 g/dL) 8.64 ± 2.46 9.12 ± 2.28 0.328
*PT(0.8 ~ 1.2 *INR) 1.79 ± 0.61 1.58 ± 0.41 0.057
*MELD score 16.17 ± 7.63 13.66 ± 6.97 0.098
*MELD-Na 17.50 ± 12.67 12.93 ± 9.31 0.052
Child-Pugh score (6 ~ 18) 8.60 ± 1.75 7.61 ± 2.23 0.015
Initial sodium (135 ~ 145 mmol/L) 134.22 ± 4.93 137.91 ± 3.46 0.000
Lowest sodium (135 ~ 145 mmol/L) 133.21 ± 5.14 128.90 ± 5.20 0.000

*PT, Prothrombin time; INR, International normalized ratio; MELD, Model for end-stage liver disease.